Stifel raised the firm’s price target on Neumora Therapeutics (NMRA) to $3 from $2 and keeps a Hold rating on the shares following Q3 earnings and hosting management at the firm’s annual Healthcare Conference. NMRA-511’s Phase 1b readout in AD agitation is expected to readout by year-end and expectations are low despite favorable initial tolerability data, making this catalyst “arguably upside-skewed,” the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NMRA:
- LB Pharmaceuticals appoints Kaya Pai Panandiker as CCO
- Neumora Therapeutics Reports Q3 2025 Progress and Financials
- Neumora Therapeutics, Inc.: Promising Growth and Innovation with Key Developments in Alzheimer’s Treatment
- Neumora Therapeutics reports Q3 EPS (35c), consensus (34c)
- Neumora Therapeutics price target raised to $8 from $6 at Needham